- Home
- NGNE vs RFMZ Comparison
NGNE vs RFMZ Comparison
Compare NGNE & RFMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- RFMZ
- Stock Information
- Founded
- NGNE 2003
- RFMZ 2021
- Country
- NGNE United States
- RFMZ United States
- Employees
- NGNE N/A
- RFMZ N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- RFMZ Trusts Except Educational Religious and Charitable
- Sector
- NGNE Health Care
- RFMZ Finance
- Exchange
- NGNE Nasdaq
- RFMZ Nasdaq
- Market Cap
- NGNE 325.3M
- RFMZ 310.1M
- IPO Year
- NGNE N/A
- RFMZ N/A
- Fundamental
- Price
- NGNE $18.48
- RFMZ $12.54
- Analyst Decision
- NGNE Strong Buy
- RFMZ
- Analyst Count
- NGNE 7
- RFMZ 0
- Target Price
- NGNE $41.86
- RFMZ N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- RFMZ 76.6K
- Earning Date
- NGNE 08-11-2025
- RFMZ 01-01-0001
- Dividend Yield
- NGNE N/A
- RFMZ 7.43%
- EPS Growth
- NGNE N/A
- RFMZ N/A
- EPS
- NGNE N/A
- RFMZ 0.65
- Revenue
- NGNE N/A
- RFMZ N/A
- Revenue This Year
- NGNE N/A
- RFMZ N/A
- Revenue Next Year
- NGNE N/A
- RFMZ N/A
- P/E Ratio
- NGNE N/A
- RFMZ $21.49
- Revenue Growth
- NGNE N/A
- RFMZ N/A
- 52 Week Low
- NGNE $6.88
- RFMZ $11.28
- 52 Week High
- NGNE $74.49
- RFMZ $14.57
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- RFMZ 44.54
- Support Level
- NGNE $19.59
- RFMZ $12.45
- Resistance Level
- NGNE $20.46
- RFMZ $12.61
- Average True Range (ATR)
- NGNE 1.23
- RFMZ 0.13
- MACD
- NGNE -0.20
- RFMZ -0.02
- Stochastic Oscillator
- NGNE 13.37
- RFMZ 13.24
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.